According to The American Diabetes Association, every $1 in $7 spent in healthcare is spent on diabetes or its complications. We look at three companies well-positioned to capture this market.
The company reported fourth-quarter results that came up short.
Shares drop after the company releases the pricing details of a recently announced capital raise.
Shares fall after the company's quarterly results and guidance come up short, but there's more to the story than meets the eye.
Shares tumble after the company announces that it is raising capital.
Shares rise after the company received some bullish praise from a Wall Street analyst.
Shares jumped after the nursing home operator issued upbeat guidance, but is the bullish move warranted?
We take a look at three small and promising healthcare companies across diagnostics, surgical products, and genetic testing.
Shares drop in response to the news of capital raise and an analyst downgrade. Here's what investors need to know.
Shares are plunging since the company reported preliminary results for the fourth quarter that missed the mark.
Shares drop after the company releases mixed earnings results and guidance.
Shares jump in response to a pair of analyst upgrades.
Shares soar after Insmed reports upbeat clinical news.
Shares pop after an SEC filing reveals that the biopharma has attracted the attention of a major financial institution.
Shares rose in response to news that a large investment management company has purchased a significant ownership position.
Optimism continues to rise for the innovative medical-device maker.
The popular direct-to-consumer bed brand is going public, but investors might want to nap on it.
Shares soar after the clinical-stage biotech releases exciting news.
Shares jump after the company releases upbeat clinical news.
The company announced a lucrative business transaction and provided a sneak peek at fourth-quarter results.